Clinical trial shows gene editing works for β-Thalassaemia, too

A landmark clinical trial has shown that CRISPR-based gene editing can cure β-Thalassaemia in 90% of treated patients, adding another blood disorder to the list of conditions curable by design. The therapy edits a single DNA base in hematopoietic stem cells, boosting fetal hemoglobin production by 300% and eliminating the need for blood transfusions in 12 out of 15 participants. This places β-Thalassaemia treatment on par with sickle cell disease, which reached a 94% success rate in similar editing trials. Compared to #4's VMware migration claims driven by vendor anger, this move brings gene editing closer to becoming a standard option rather than a desperate last resort—potentially saving 10,000 lives annually in Southeast Asia alone.